{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:53:29Z","timestamp":1778741609747,"version":"3.51.4"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Specially created pediatric formulations have the potential to improve the acceptability, effectiveness, and accuracy of dosing of artemisinin-based combination therapy (ACT) in young children, a patient group that is inherently vulnerable to malaria. Artemether-lumefantrine (AL) Dispersible is a pediatric formulation of AL that is specifically tailored for the treatment of children with uncomplicated\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum<\/jats:named-content>\n            malaria, offering benefits relating to efficacy, convenience and acceptance, accuracy of dosing, safety, sterility, stability, and a pharmacokinetic profile and bioequivalence similar to those of crushed and intact AL tablets. However, despite being the first pediatric antimalarial to meet World Health Organization (WHO) specifications for use in infants and children who are \u22655 kg in body weight and its inclusion in WHO Guidelines, there are few publications that focus on AL Dispersible. Based on a systematic review of the recent literature, this paper provides a comprehensive overview of the clinical experience with AL Dispersible to date. A randomized, phase 3 study that compared the efficacy and safety of AL Dispersible to those of crushed AL tablets in 899 African children reported high PCR-corrected cure rates at day 28 (97.8% and 98.5% for AL Dispersible and crushed tablets, respectively), and the results of several subanalyses of these data indicate that this activity is observed regardless of patient weight, food intake, and maximum plasma concentrations of artemether or its active metabolite, dihydroartemisinin. These and other clinical data support the continued use of pediatric antimalarial formulations in all children &lt;5 years of age with uncomplicated malaria when accompanied by continued monitoring for the emergence of resistance.\n          <\/jats:p>","DOI":"10.1128\/aac.00014-15","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T15:24:53Z","timestamp":1432740293000},"page":"4366-4374","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria"],"prefix":"10.1128","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-7596","authenticated-orcid":false,"given":"Quique","family":"Bassat","sequence":"first","affiliation":[{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Cl\u00ednic\u2014Universitat de Barcelona, Barcelona, Spain"},{"name":"Centro de Investiga\u00e7\u00e3o em Sa\u00fade de Manhi\u00e7a (CISM), Maputo, Mozambique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhards","family":"Ogutu","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoulaye","family":"Djimde","sequence":"additional","affiliation":[{"name":"Malaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin","family":"Stricker","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"World malaria report 2014","author":"WHO","year":"2014","unstructured":"WHO. 2014. World malaria report 2014. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. 2015. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland.","edition":"3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-S1-S7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.771167"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-12"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2006.01769.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-365"},{"key":"e_1_3_2_9_2","volume-title":"The WHO prequalification project","author":"WHO","year":"2013","unstructured":"WHO. 2013. The WHO prequalification project. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_10_2","volume-title":"Forty-eighth report. WHO technical report series no. 986","author":"WHO Expert Committee on Specifications for Pharmaceutical Preparations","year":"2014","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. 2014. Good manufacturing practices for pharmaceutical products: main principles. Annex 2. Forty-eighth report. WHO technical report series no. 986. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/TRS986annex2.pdf?ua=1. Accessed 20 May 2015."},{"key":"e_1_3_2_11_2","unstructured":"US Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). 2014. Guidance for industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM389370.pdf. Accessed 20 May 2015."},{"key":"e_1_3_2_12_2","volume-title":"Guideline on the investigation of bioequivalence","author":"European Medicines Agency","year":"2010","unstructured":"European Medicines Agency. 2010. Guideline on the investigation of bioequivalence. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Accessed 20 May 2015."},{"key":"e_1_3_2_13_2","volume-title":"Instructions for application and authorisation for generics","author":"Swissmedic","year":"2009","unstructured":"Swissmedic. 2009. Instructions for application and authorisation for generics. Swissmedic, Bern, Switzerland."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.11-0069"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66416-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.991"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-240"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-58"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-184"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61492-0"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-253"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-369"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2010.02477.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01115-10"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-33"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-S1-S4"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.51"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70327-5"},{"key":"e_1_3_2_29_2","unstructured":"WHO. 2011. Riamet Dispersible\/Coartem Dispersible: summary of product characteristics. WHOPAR Part 4. WHO Geneva Switzerland. http:\/\/apps.who.int\/prequal\/whopar\/whoparproducts\/MA069part4v1.pdf."},{"key":"e_1_3_2_30_2","volume-title":"Eurartesim: summary of product characteristics","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency. 2011. Eurartesim: summary of product characteristics. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001199\/WC500118113.pdf."},{"key":"e_1_3_2_31_2","volume-title":"Innovation in malaria drug packaging: Coartem and Coartem Dispersible","author":"International Pharmaceutical Industry (IPI)","year":"2009","unstructured":"International Pharmaceutical Industry (IPI). 2009. Innovation in malaria drug packaging: Coartem and Coartem Dispersible. International Pharmaceutical Industry, London, United Kingdom."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2004.09.013"},{"key":"e_1_3_2_33_2","unstructured":"Consume Reports. 2014. Are drugs like Apotex medication made in India safe? FDA sanctions against some Indian drug plants raise concerns about the U.S. generic-drug supply. http:\/\/www.consumerreports.org\/cro\/news\/2014\/04\/are-generic-drugs-made-in-india-safe\/index.htm. Accessed 20 May 2015."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-251"},{"key":"e_1_3_2_35_2","volume-title":"The fixed-dose combination of artesunate and mefloquine: a new, effective tool in the fight against malaria\u2014executive report","author":"Drugs for Neglected Diseases initiative (DNDi)","year":"2012","unstructured":"Drugs for Neglected Diseases initiative (DNDi). 2012. The fixed-dose combination of artesunate and mefloquine: a new, effective tool in the fight against malaria\u2014executive report. Drugs for Neglected Diseases Initiative, Geneva, Switzerland."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0265"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70187-0"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/591096"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/522985"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-254"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit077"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-291"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70024-1"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00014-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00014-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:07:48Z","timestamp":1645484868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00014-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1128\/AAC.00014-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.00014-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"2015-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}